

Tim A Labeur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7175611/publications.pdf>

Version: 2024-02-01

16
papers

264
citations

933447

10
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

579
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. <i>Hpb</i> , 2018, 20, 83-92.	0.3	45
2	Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Liver Cancer</i> , 2019, 8, 255-270.	7.7	30
3	Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. <i>Hpb</i> , 2017, 19, 735-740.	0.3	27
4	Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. <i>Liver International</i> , 2020, 40, 215-228.	3.9	27
5	A Pilot Study on Hepatobiliary Scintigraphy to Monitor Regional Liver Function in ⁹⁰ Y Radioembolization. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1430-1436.	5.0	22
6	Validation of the Mayo Clinic Staging System in Determining Prognoses of Patients With Perihilar Cholangiocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1930-1939.e3.	4.4	15
7	Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2018, 57, 1467-1474.	1.8	13
8	Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. <i>Abdominal Radiology</i> , 2019, 44, 2740-2750.	2.1	13
9	Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 230-238.	2.0	13
10	Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 1483-1492.	1.5	13
11	Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 82-94.	4.4	11
12	Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. <i>Oncologist</i> , 2020, 25, e1274-e1279.	3.7	11
13	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma – a substudy of the SORAMIC trial. <i>Acta Oncologica</i> , 2020, 59, 1028-1035.	1.8	11
14	The utility of ^{99m} Tc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2020, 41, 740-749.	1.1	8
15	Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy. <i>Cancers</i> , 2021, 13, 5427.	3.7	5
16	Response to: Prognostication of HCC patients under sorafenib is not always possible. <i>Liver International</i> , 2020, 40, 1243-1244.	3.9	0